KR880001693A - 신규의 18- 페닐오 에스트란 유도체 - Google Patents

신규의 18- 페닐오 에스트란 유도체 Download PDF

Info

Publication number
KR880001693A
KR880001693A KR1019870007839A KR870007839A KR880001693A KR 880001693 A KR880001693 A KR 880001693A KR 1019870007839 A KR1019870007839 A KR 1019870007839A KR 870007839 A KR870007839 A KR 870007839A KR 880001693 A KR880001693 A KR 880001693A
Authority
KR
South Korea
Prior art keywords
steroid
group
oxygen
carbon atoms
optionally
Prior art date
Application number
KR1019870007839A
Other languages
English (en)
Inventor
파울 드용 헨드릭
요하네스반덴호 이벨 마르티누스
Original Assignee
에이.지.제이.베르 메렌·에이.디.도우마
악조 엔.브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이.지.제이.베르 메렌·에이.디.도우마, 악조 엔.브이 filed Critical 에이.지.제이.베르 메렌·에이.디.도우마
Publication of KR880001693A publication Critical patent/KR880001693A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

신규의 18-페닐오 에스트란 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기식을 갖는 오에스트란게의 신규한 18-페닐 스테로이드
    여기에서 R1과 R2는 각각 H또는 (1-4c)탄화수소 래디칼을 나타내거나, 함께 (2-6c)탄화수소 래디칼을 나타내며, R3는 H또는 임의로 하이드록실 치환체를 갖는 (1-4c) 탄화수소 래디칼을 나타내며, R4는 하이드록실기 또는 에스테르 또는 에트르기, 또는 R3와 함께 산소 또는 산소를 포함하는 헤테로고리 환 시스템을 나타내며, 점선은 기본구조의 9위치와 10위치의 탄소원자 사이에 임의로 이중결합이 존재함을 나타냄.
  2. 제1항에서 있어서, R3가 임의의 하이드록시 치환체를 갖는 (2-3c) 탄화수소기이며, R4가 하이드록실기인 것을 특징으로 하는 스테로이드.
  3. 제1항 또는 제2항에 있어서, R1이 1-3개의 탄소 원자를 포함하는 포화된 알킬기인것을 특징으로 하는 스테로이드.
  4. 제1항, 제2항, 제3항중 어느 한 항에 있어서, R2가 탄소수 1-3개를 포함하는 포화된 알킬기인 것을 특징으로 하는 스테로이드.
  5. 스테로이드 기본구조상의 위치 3 및 임의로 위치 17에 보호된 케톤기를 갖는 상응하는 화합물이 비보호 되며, 17β-하이드록실기가 에스테르화 되거나, 또는 에테르화 되거나 17-산소기가 산소를 포함하는 헤테로 고리 환 시스템을 전환되는 것을 특징으로 하는 제1항 내지 제4항에 의한 화합물을 제조하는 방법.
  6. 제1항에 의한 화합물중 최소한 한종류를 활성 성분으로 포함하고 있는 임신 종료 또는 임신-억제활성을 갖는 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870007839A 1986-07-23 1987-07-20 신규의 18- 페닐오 에스트란 유도체 KR880001693A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8601903 1986-07-23
NL8601903 1986-07-23

Publications (1)

Publication Number Publication Date
KR880001693A true KR880001693A (ko) 1988-04-26

Family

ID=19848343

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870007839A KR880001693A (ko) 1986-07-23 1987-07-20 신규의 18- 페닐오 에스트란 유도체

Country Status (15)

Country Link
US (1) US4808710A (ko)
EP (1) EP0254341B1 (ko)
JP (1) JPS6335595A (ko)
KR (1) KR880001693A (ko)
CN (1) CN87106126A (ko)
AU (1) AU598836B2 (ko)
CA (1) CA1284318C (ko)
DE (1) DE3761308D1 (ko)
DK (1) DK383887A (ko)
ES (1) ES2015047B3 (ko)
FI (1) FI84274C (ko)
GR (1) GR3001005T3 (ko)
NZ (1) NZ221019A (ko)
PT (1) PT85395B (ko)
ZA (1) ZA874863B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992485A (en) * 1988-10-11 1991-02-12 The Dow Chemical Company Microporous peek membranes and the preparation thereof
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
ZA929315B (en) * 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
AU710139B2 (en) * 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
AU2004217988C1 (en) * 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
WO2005066194A1 (en) * 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
EP2576582B1 (en) 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CA2994422A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
ES2861524T3 (es) 2016-01-19 2021-10-06 Corcept Therapeutics Inc Diagnóstico diferencial del Síndrome de Cushing Ectópico
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1255345A (en) * 1916-05-20 1918-02-05 Arthur L Shaw Conveyer.
US3100204A (en) * 1960-04-20 1963-08-06 Merck & Co Inc Haloethisterone compounds
US3074978A (en) * 1961-01-11 1963-01-22 Roussel Uclaf Process for the preparation of 13beta-n-propyl-delta4-gonene-17beta-ol-3-one and the intermediates in the preparation thereof
US3177205A (en) * 1963-03-01 1965-04-06 Syntex Corp 19-lower-alkyl-10alpha-derivatives of cortical hormones
JPS4118820Y1 (ko) * 1965-09-22 1966-09-02
BE697838A (ko) * 1966-11-11 1967-10-02
US3725439A (en) * 1971-01-07 1973-04-03 Merck & Co Inc 13-carbocyclic-3-keto-4-gonenes
US4167517A (en) * 1976-06-14 1979-09-11 Veb Jenapharm Gona-4,9(10)-dienes and process of producing the same
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained

Also Published As

Publication number Publication date
DK383887D0 (da) 1987-07-22
NZ221019A (en) 1989-12-21
ES2015047B3 (es) 1990-08-01
US4808710A (en) 1989-02-28
JPS6335595A (ja) 1988-02-16
CA1284318C (en) 1991-05-21
AU598836B2 (en) 1990-07-05
DE3761308D1 (de) 1990-02-08
EP0254341B1 (en) 1990-01-03
FI84274C (fi) 1991-11-11
FI873193A0 (fi) 1987-07-20
FI873193A (fi) 1988-01-24
EP0254341A1 (en) 1988-01-27
CN87106126A (zh) 1988-05-11
FI84274B (fi) 1991-07-31
PT85395B (pt) 1990-04-30
DK383887A (da) 1988-01-24
ZA874863B (en) 1988-01-13
PT85395A (en) 1987-08-01
AU7596987A (en) 1988-01-28
GR3001005T3 (en) 1991-12-30

Similar Documents

Publication Publication Date Title
KR880001693A (ko) 신규의 18- 페닐오 에스트란 유도체
KR880009036A (ko) 신규 ii-아릴 스테로이드 유도체
KR950701640A (ko) 에리트로마이신 유도체(eryhromycin derivative)
KR850001691A (ko) 디하이드로피리딘 a 화합물의 속효성 고형제제의 제조방법
KR927003493A (ko) 이리도이드 유도체 및 그의 의약으로서의 사용
SE8602738D0 (sv) Gasoline composition
KR890009968A (ko) 신규의 11-아릴스테로이드 화합물
KR920701162A (ko) 퀴놀린 유도체, 당해 유도체를 함유하는 항궤양제 및 당해 유도체의 제조방법
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
KR830007562A (ko) 퀴놀린 카르복실산 유도체의 제조방법
KR890014107A (ko) 백금 화학 요법약제
KR900007415A (ko) 기억장해 개선약
KR920700656A (ko) 과유지질혈증 및/또는 아테롬성 동맥경화증 처리약물
KR840005116A (ko) 옥사졸초산 유도체의 제조방법
KR920701220A (ko) 신규의 복핵 백금 착체 및 이를 유효성분으로하는 항종양제
KR840008342A (ko) 모르포린 유도체의 제조방법
KR890008134A (ko) 브라씨노스테로이드 유도체 및 식물 성장 조절제
KR920702685A (ko) 4,6-o- 히드록시포스포릴글루코사민 유도체
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
KR840005427A (ko) 카르보스티릴 유도체의 제조방법
KR960700258A (ko) 5-0-데소사미닐에리쓰로노라이드 유도체
KR830007693A (ko) 7-아미노 세펨 화합물을 제조하는 개량방법
KR870010070A (ko) 모라노린 유도체의 제조법
KR930021653A (ko) 단일 4차 2, 16-비스피페리디닐안드로스탄 유도체
KR920002497A (ko) 스테롤 화합물

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid